Oral fluoroquinolones and the risk of retinal detachment

JAMA

Volumn 307, Issue 13, 2012, Pages 1414-1419

  Etminan, Mahyar ^a,b   Forooghian, Farzin ^b   Brophy, James M ^c   Bird, Steven T ^d   Maberley, David ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SHORT ACTING DRUG; QUINOLONE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; BONE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL INFECTION; HIGH RISK PATIENT; HUMAN; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; RISK ASSESSMENT; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; AGED; CANADA; CASE CONTROL STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; RISK;

ADMINISTRATION, ORAL; ADULT; AGED; BRITISH COLUMBIA; CASE-CONTROL STUDIES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; RISK;

EID: 84859400803     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.383     Document Type: Article

References (30)

1. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med. 2006;354(13):1352-1361.
2. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007;29(4):374-379. (Pubitemid 46349590)
3. Leone R, Venegoni M, Motola D, et al. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions. Drug Saf. 2003;26(2):109-120. (Pubitemid 36188561)
4. Al-Amri AM. Corneal perforation associated with topically applied gatifloxacin. Cornea. 2008;27(3):370-371. (Pubitemid 351440878)
5. Samarakoon N, Harrisberg B, Ell J. Ciprofloxacin-induced toxic optic neuropathy. Clin Experiment Ophthalmol. 2007;35(1):102-104. (Pubitemid 46195939)
6. US Department of Health and Human Services; US Food and Drug Administration. Labeling revision: supplement approval letter (NDA 21158/S-018). http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/021158s018ltr.pdf. Accessed January 27, 2011.
7. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture.NEngl JMed. 1995;332(3):193.
8. Rampal S, Kaur R, Sethi R, Singh O, Sood N. Ofloxacin-associated retinopathy in rabbits: role of oxidative stress. Hum Exp Toxicol. 2008;27(5):409-415.
9. Sirbat D, Saudax E, Hurault de Ligny B, Hachet E, Raspiller A. Serous macular detachment of the neuroepithelium and flumequine. J Fr Ophtalmol. 1983;6(10):829-836. (Pubitemid 14185580)
10. Health Canada. Adverse Reaction Report No. 126410. Ottawa, Ontario: Health Canada; 1999.
11. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003;36(11):1404-1410. (Pubitemid 36702874)
12. Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49(9):4089-4095.
13. Sodhi A, Leung LS, Do DV, Gower EW, Schein OD, Handa JT. Recent trends in the management of rhegmatogenous retinal detachment. Surv Ophthalmol. 2008;53(1):50-67.
14. Population Data British Columbia. Discharge abstract database. http://www.popdata.bc.ca/data/internal/health/dad. Accessed January 25, 2012.
15. Ministry of Health. Medical services plan of British Columbia. http://www.health.gov.bc.ca/msp/index.html. Accessed January 25, 2012.
16. British Columbia Ministry of Health. PharmaNet. http://www.health.gov.bc. ca/pharmacare/pharmanet/netindex.html. Accessed January 25, 2012.
17. Williams JI, Young W. Inventory of Studies on the Accuracy of Canadian Health Administrative Databases. Toronto, ON: Institute for Clinical Evaluative Sciences; 1996.
18. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525-2531.
19. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411-E419.
20. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205-213. (Pubitemid 20126858)
21. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801-1807. (Pubitemid 36960927)
22. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154(9):854-864. (Pubitemid 33000813)
23. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303. (Pubitemid 43797117)
24. Sharma T, Gopal L, Shanmugam MP, et al. Retinal detachment in Marfan syndrome: clinical characteristics and surgical outcome. Retina. 2002;22(4):423-428. (Pubitemid 35025517)
25. Tsai WC, Hsu CC, Chen CP, et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 2011;29(1):67-73.
26. Reviglio VE, Hakim MA, Song JK, O'Brien TP. Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. BMC Ophthalmol. 2003;3:10.
27. Keren G, Alhalel A, Bartov E, et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci. 1991;32(8):2388-2392.
28. Williams RJ, Attia E, Wickiewicz TL, Hannafin JA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism.AmJ Sports Med. 2000;28:364-369. (Pubitemid 30394760)
29. Harrell RM. Fluoroquinolone-induced tendinopathy: what do we know? South Med J. 1999;92:622-625. (Pubitemid 29270195)
30. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002;324(7349):1306-1307. (Pubitemid 34606771)